156 It appears that clinically significant DDIs caused by delayed gastric emptying affecting the pharmacokinetics of the victim drugs are unlikely to occur
As we noted, one inherent complexity to managing GLP-1s is that the same drug will have a different name and price according to indication
Medical conditions may include but are not limited to diabetes, hypothyroidism, gastroesophageal reflux disease (GERD), Barretts esophagus, dysphagia, esophagitis, cirrhosis, prior abdominal surgeries or procedures, gastric polyps, varying autoimmune diseases, pain disorders, psychiatric diseases, neuromuscular disorders, obstructive sleep apnea (OSA), or general ASA physical status classifications
And a lot of that process is to going through regulatory approval process, which takes time, and rightfully so because we want to make sure that these medicines are safe and effective
Preventive Services Task Force confirms that intensive follow-up improves weight loss outcomes